| Ytd | -60.27% | |
| 1y | -82.07% |
| Open | 0.33 | Prev Close | 0.32 | Low | 0.31 | High | 0.33 | Mkt Cap | 9.84M |
| Vol | 131.54K | Avg Vol | 1.45M | EPS | -3.71 | P/E | -0.08 | Forward P/E | -0.26 |
| Beta | 0.90 | Short Ratio | 0.71 | Inst. Own | 67.52% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-18 | 50-d Avg | 0.40 | 200-d Avg | 0.52 | 1yr Est | 11.00 |
GTBP News
Issued on behalf of GT Biopharma, Inc. (Nasdaq: GTBP) A clinical-stage immuno-oncology company has m
Increased integration of artificial intelligence–based tools across the discovery and engineering of
GT Biopharma says AI-driven drug discovery tools are accelerating pipeline development and may yield
/PRNewswire/ -- USA News Group Market Commentary - Start with the number that makes everyone do a do
https://www.sec.gov/ix?doc=/Archives/edgar/data/109657/000149315226024913/form8-k.htm
/PRNewswire/ -- USA News Group News Commentary - For more than two decades, B7-H3 sat on the shortli
GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(0.11) per share which missed the analyst c
Phase 1 trial evaluating GTB-3650 TriKE ® remains ongoing, with additional updates anticipated in 2H
GTB-5550 is now the 3rd TriKE ® to enter the clinic and an expansion into a broader solid tumor oppo
GT Biopharma Inc. (NASDAQ:GTBP) on Thursday dosed the first patient on a Phase 1 dose-escalation bas
GT Biopharma doses first patient in Phase 1 GTB-5550 trial targeting B7-H3-positive solid tumors wit
Cogent Biosciences (NASDAQ: COGT - Get Free Report) and GT Biopharma (NASDAQ: GTBP - Get Free Report
GT Biopharma (GTBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about th
GT Biopharma (GTBP) witnesses a hammer chart pattern, indicating support found by the stock after lo
SAN FRANCISCO, CALIFORNIA, March 11, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NA
GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(4.84) per share. This is a 191.57 percent
Year Ended December 31, 2025 Financial SummaryCash Position: The Company had cash and cash equivalen
Phase 1 trial evaluating GTB-3650 TriKE ® continues to actively enroll, with the next update anticip
SAN FRANCISCO, CALIFORNIA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NAS
GTB-5550 Phase 1 dose escalation basket trial expected to initiate mid-2026Phase 1 protocol allows m
GTB-5550 Phase 1 dose escalation basket trial expected to initiate mid-2026 Phase 1 protocol allows
GT Biopharma targets a portion of the estimated $362 billion global solid tumor market Preliminary,
GT Biopharma Inc. (NASDAQ: GTBP) on Thursday said it submitted an investigational new drug (IND) app
GT Biopharma submitted an IND application for GTB-5550 TriKE for solid tumors. Phase 1 trial planned
GT Biopharma targets a portion of the estimated $362 billion global solid tumor market with its B7-H
VANCOUVER, British Columbia, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Equity Insider News Commentary - The
Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC , Dec. 19, 2025 /PRNewswire/ -- USA News Group
/PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia eliminat
Within this landscape, GT Biopharma (NASDAQ:GTBP) is advancing a proprietary platform designed to h
NAPLES, FL / ACCESS Newswire / November 19, 2025 / Patients battling aggressive blood cancers face l
